13 matches for your search in the start-up spotlight
rss
Glox Therapeutics awarded share of £3M Collaborative Discovery Programme funding from Cystic Fibrosis Antimicrobial Resistance Syndicate
28-Jan-2025
Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, announced it has been awarded a share of the £3 million Collaborative Discovery Programme (CDP) launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) ...
The financing will be used to support the clinical development of a next generation antibacterial combination
14-Dec-2023
Antabio SAS, a clinical stage biopharmaceutical company developing novel treatments for severe drug-resistant bacterial infections, announced that it has raised €25m in a series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from the company’s historical investors ...
Spin-off has built a platform that creates new ways to tackle bacterial infections
11-Dec-2023
Obulytix, a groundbreaking biotech spin-off founded by seasoned experts in phage lysin research from Ghent University and KU Leuven, is set to revolutionize the fight against antimicrobial resistance with its novel phage lysin-based antibiotics. The innovative, phage lysin-based platform – ...
Spin-out from the Universities of Glasgow and Oxford
21-Nov-2023
Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria. The Company will use ...
In minutes rather than days to prescribe the optimal antibiotic
13-Sep-2023
Glasgow diagnostics spinout Microplate Dx has closed a £2.5M seed funding round to develop its point-of-care diagnostic platform which can confirm the presence of bacteria and guide a patient’s doctor to effective treatment by rapidly identifying effective antibiotics to use and which ones to ...
By optimizing nature’s defenders, the team has produced unprecedented phage treatments
29-Jun-2023
The new biotech venturePHIOGENis a spin-off company fromBaylor College of Medicine’sTAILOR Labs, one of the United States only academic phage therapy cores with a decade’s worth of revolutionary research related to bacteriophages, viruses that infect and destroy bacteria. The company made its ...
SANTERO announces a €8 million Series A funding round led by Newton Biocapital
12-Jun-2023
Newton Biocapital (NBC), a venture capital firm focused on investing and growing early-stage life sciences companies in Europe and Japan targeting chronic health conditions, has announced the closing of a successful €8 million Series A financing round for Santero. SANTERO, a spin-off company of ...
INCATE catalyzes critical growth stage at Invitris
11-May-2023
INCATE has selected Invitris as the first venture to receive €250,000 in “Stage II Funding” that will allow Invitris to complete spin-out from Chair of Physics of Synthetic Biological Systems at the Technical University of Munich (TUM) and further its mission to scale the production of phages, ...
Vésale Bioscience receives €1.8M grant from European Innovation Council for PhageDiag project
23-Jan-2023
Vésale Bioscience, a company in the research and development of solutions and treatments using phage therapy for multi-resistant infections, announces it has received €1.8M ($1.9M) in grants fromthe European Innovation Council (EIC) Accelerator Fund for its PhageDiag project, a phagogram using ...
Seed financing to advance its machine learning-based platform for discovery of novel anti-infectives addressing antimicrobial resistance
16-Mar-2022
ArrePath, an anti-infective drug discovery start-up addressing the global health challenge of drug resistant infections, announced that it has raised $20 million in seed financing to advance its proprietary, machine learning (ML)-based platform for the discovery of new classes of anti-infectives ...
